About
Insuline Medical is focused on improving the performance of current insulin treatment methods by better utilizing human physiology. Its flagship product, the InsuPad, is composed of a disposable injection window (Fenster) and a reusable, rechargeable control unit using skin-condition stabilization technology. By gently warming the skin, the device increases blood flow, helping the body absorb insulin more quickly and effectively. InsuPad is noninvasive, safe, simple, easy to use, and has Medical Device Directive (CE mark) approval for the European Union. Insuline's InsuPad offers significant clinical benefits to patients, physicians, and health insurance providers. Insuline Medical has initiated commercialization in Germany in collaboration with J&J (LifeScan) and in Israel with DYN diagnostics, exclusive representatives of Roche Diagnostics in Israel.
Funding history · 3 rounds · $6.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is InsuLine Medical's primary focus and flagship product?
- InsuLine Medical focuses on improving insulin treatment methods. Its flagship product, the InsuPad, is a noninvasive device that warms the skin to increase blood flow, aiding quicker and more effective insulin absorption.
- When was InsuLine Medical founded?
- InsuLine Medical was founded in February 2007.
- What is the operational status of InsuLine Medical?
- InsuLine Medical is currently inactive, having ceased operations in June 2019.
- What was InsuLine Medical's total funding raised?
- InsuLine Medical raised a total of $6,500,000 USD across its funding rounds.
- When did InsuLine Medical go public and on which exchange?
- InsuLine Medical had an IPO in July 2010 on the TASE (Tel Aviv Stock Exchange).
- Which investors participated in InsuLine Medical's funding rounds?
- Pontifax invested in InsuLine Medical in April 2012, and IBI Investment House participated in a convertible bond round in August 2018. For a full financing history, users can refer to startupim.
- What was InsuLine Medical's last funding round?
- InsuLine Medical's last funding round was a Convertible Bond in August 2018, raising $2,800,000 USD.
- With which companies did InsuLine Medical collaborate for commercialization?
- InsuLine Medical initiated commercialization in Germany in collaboration with J&J (LifeScan) and in Israel with DYN diagnostics, which represents Roche Diagnostics.
- Did InsuLine Medical receive any grants or special funding?
- InsuLine Medical was set to receive funding from Israel's Chief Scientist in March 2016 for its injection site treatment and stabilization technology with long-acting insulin.